Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-27
2005-09-27
Turner, Sharon L. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S350000
Reexamination Certificate
active
06949505
ABSTRACT:
Disclosed are methods and compositions for maintaining neural pathways in a mammal including: enhancing survival of neurons at risk of dying; inducing cellular repair of damaged neurons and neural pathways; stimulating neurons to maintain their differentiated phenotype; and promoting dendritic outgrowth, including maintaining dendritic arbors and regenerating dendritic architecture. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration. In another embodiment, the invention provides methods and compositions which include a morphogen or morphogen-stimulating agent, and a nerve trophic factor or nerve trophic factor-stimulating agent at concentrations effective for stimulating dendrite outgrowth. The morphogen and the nerve trophic factor can be admixed in combination.
REFERENCES:
patent: 4801575 (1989-01-01), Pardridge
patent: 4877864 (1989-10-01), Wang et al.
patent: 4968590 (1990-11-01), Kuberasampath et al.
patent: 4975526 (1990-12-01), Kuberasampath et al.
patent: 5011486 (1991-04-01), Aebischer et al.
patent: 5011691 (1991-04-01), Oppermann et al.
patent: 5013649 (1991-05-01), Wang et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5106626 (1992-04-01), Parsons et al.
patent: 5108753 (1992-04-01), Kuberasampath et al.
patent: 5141905 (1992-08-01), Rosen et al.
patent: 0148155 (1985-01-01), None
patent: WO92/00382 (1992-01-01), None
patent: WO 92/15323 (1992-09-01), None
Lein et al. Neuron 15 (1995) 597-604.
Jackowski British J. of Neurosurgery 9 (1995) 303-317.
Skolnick et al., Trends in Biotech., 18(1):34-39, 2000.
Zheng et al., Pathology Research and Practice 1992 188(8):1104-21.
Kawamata et al., Neuroreport May 11, 1998, 9(7):1441-5.
Ren et al., Neuropharm., Mar. 3, 2000, 39(5):860-65.
Hulley et al., J. of Neurosci. Res., Jul. 15, 1998, 53(2):129-34.
Chen et al., J. of Neurobiol., Feb. 15, 1999, 38(3):428-39.
Chao et al., Neurobiol. Of aging, Jan.-Feb., 2003, 24(1):105-16.
Ditlevsen et al., J. of Neurochem., Feb., 2003, 84(3):546-56.
Basler et al. (1993), “Control of Cell Pattern in the Neural Tube: Regulation of Cell Differentiation by dorsalin-1, a Novel TGFB Family Member,” 73Cell687-702.
Cohen Charles M.
Higgins Dennis
Oppermann Hermann
Ozkaynak Engin
Rueger David C.
Curis, Inc.
Fish & Neave IP Group Ropes & Gray LLP
The Research Foundation of State University of New York
Turner Sharon L.
LandOfFree
Morphogen-induced dendritic growth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Morphogen-induced dendritic growth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Morphogen-induced dendritic growth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3413949